C5 Acquisition Registers for $250M IPO

IPO

C5 Acquisition filed to offer 25 million units, each consisting of one share and one-half of a warrant. The sponsor has committed to purchasing at least $13.54 million in private placement warrants.

The SPAC’s acquisition focus is on companies engaged in national security innovation in three key sectors: space, cybersecurity and energy transition.

CEO and director Robert Meyerson from May 2016 to October 2017 was president of Blue Origin, the aerospace company founded and owned by Jeff Bezos.

Cantor and Moelis are joint book-running managers.

The SPAc expects to apply for a listing on the NYSE under CXAC.U. Read more.

 

Total
0
Shares
Related Posts
Read More

Phoenix Biotech Receives Nasdaq Warning

Phoenix in June signed a merger agreement with CERo Therapeutics at a pro forma equity capitalization of $145 million. The target is an immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms.